Health Care & Life Sciences
Articles
Indiana Seed Fund makes 11th investment
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
Amylin and Lilly seek expanded Byetta approval
Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Wednesday they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta, which could bolster sales as the companies try to get approval for a new, longer-lasting version of the drug.
Lilly Alzheimer’s imaging agent to get priority FDA review
Eli Lilly and Co. said the Food and Drug Administration will perform a faster review of florbetapir, an imaging agent that may help diagnose Alzheimer's disease.
Clarian, Morgan clear way for merger
The merger of Morgan Hospital & Medical Center into Clarian Health got the go-ahead from all parties in the past week, opening the way for Morgan to bring on new doctors to its facilities.
Zimmer looks to China to reignite growth
Zimmer Holdings Inc. completed an acquisition in China on Tuesday, but recession hangovers in the United States and Europe are trumping all other factors and keeping the company’s growth bottled up for now.
WellPoint’s New York rate hike to face scrutiny
WellPoint Inc. and other U.S. health insurers will have to provide justification for any increases to customers’ premiums of more than 10 percent next year, according to federal regulations published Tuesday.
Duke/Browning team to develop building at new Wishard
The team, which plans to build an office building in the 200,000-square-foot range, beat out six other groups that submitted proposals.
WellPoint spent $1.1M lobbying feds in third quarter
Indianapolis-based WellPoint Inc. spent $1.1 million lobbying the federal government in the third quarter, as it focused on several issues tied to the health care overhaul Congress passed in March.
Lilly Endowment gives $35M to start pharmacy school
Manchester College will use money to launch the state’s third program offering doctorates in pharmacy.
OneAmerica moves beyond small employers, eyes big retirement plans
OneAmerica Financial Partners Inc. last month launched an insurance product aimed at landing far larger retirement plans than it has served before, and significantly growing its assets.
Clarian off to slow start in insurance
Clarian Health got few takers in its first year offering a health care benefits program to large employers, but the Indianapolis-based hospital system is undeterred in growing its budding insurance services business.
Conseco name lives on at downtown arena
CNO Financial Group appears to have backed away from plans to change the name of the Indiana Pacers home it sponsors, Conseco Fieldhouse, even though the company no longer uses the Conseco name.
Basiles donate to new Wishard Hospital
$300,000 from the local philanthropists is the hospital’s first naming-rights gift.
Daniels says he’d sign statewide smoking ban
Gov. Mitch Daniels said towns and cities have shown it’s possible to enact smoking bans with significant benefits and minimal cost.
Indiana may cut Medicaid services to check costs
The state Medicaid actuary projected Indiana’s share of the program’s costs will rise by about $1.46 billion this fiscal year, by about $1.84 billion in the 2012 fiscal year and by about $2 billion in the 2013 fiscal year unless some services are cut.
Turbulent Indiana General Assembly just ahead
Scarce resources promise to vex lawmakers charged with writing a new budget when the Legislature convenes in January.
Biomet owners look to arrange $11B marriage
Warsaw-based Biomet Inc. could get a whole lot bigger if rumors prove true that its owners have made a bid for U.K.-based rival Smith & Nephew plc.
Health insurance investors unfazed by court ruling
This week’s ruling by a federal judge could force Congress to rework the new health law to avoid a health insurance market collapse. But the decision had little to no effect on investor sentiment toward WellPoint Inc. and its peers.
Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.